XML 36 R15.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Financial Instruments | 12 Months Ended
--- | ---
Dec. 31, 2023
Financial Instruments [Abstract] |
Financial Instruments Disclosure | FINANCIAL INSTRUMENTS The Company has limited involvement with derivative financial instruments and does not use them for trading purposes. The Company enters into certain interest rate and cross currency swap agreements in order to manage its exposure to changes in interest rates. The amount of the Company’s fixed obligation interest payments may change based upon the expiration dates of its interest rate and cross currency swap agreement and the level and composition of its debt. The Company also enters into certain foreign currency forward contracts to limit the Company’s exposure to currency fluctuations on the respective hedged items. For additional disclosures on derivative instruments regarding balance sheet location, fair value, and the amounts reclassified into other comprehensive income and the effective portion of the cash flow hedges, also see Note 7 and Note 11 to the consolidated financial statements. As also mentioned in Note 10, the Company has designated its euro-denominated debt as a hedge of a portion of its net investment in a euro-denominated foreign subsidiary. Cash Flow Hedges The Company has entered into a number of cross currency swaps designated as cash flow hedges. The agreements convert borrowings under the Company’s credit facility into synthetic Swiss franc debt, which allows the Company to effectively change the floating rate SOFR-based interest payments, excluding the credit spread, to a fixed Swiss franc income or expense as follows:
Agreement Date |  | Amount Converted |  | Effective Swiss Franc Interest Rate |  | Maturity Date
June 2019 |  | $50 million |  | (0.82)% |  | June 2023
November 2021 |  | $50 million |  | (0.67)% |  | November 2023
June 2021 |  | $50 million |  | (0.73)% |  | June 2024
June 2021 |  | $50 million |  | (0.59)% |  | June 2025
December 2023 |  | $50 million |  | 1.04% |  | November 2026
November 2023 |  | $50 million |  | 1.16% |  | November 2026
June 2023 |  | $50 million |  | 1.55% |  | June 2027
The Company amended all active cross currency swap agreements to replace all references of LIBOR to SOFR as the interest rate benchmark to align with the amendment to the Company's Credit Facility Agreement, as discussed in Note 10 to the consolidated financial statements. As part of these amendments, the corresponding fixed Swiss franc interest rates were amended as well to reflect the change in the benchmark. The Company’s cash flow hedges are recorded gross at fair value in the consolidated balance sheet at December 31, 2023 and 2022 and are disclosed in Note 7 to the consolidated financial statements. A derivative gain of $7.3 million based upon interest rates at December 31, 2023 is expected to be reclassified from other comprehensive income (loss) to earnings in the next 12 months. Through December 31, 2023, no hedge ineffectiveness has occurred in relation to these cash flow hedges. Other Derivatives The Company primarily enters into foreign currency forward contracts in order to economically hedge short-term intercompany balances largely denominated in Swiss franc, other major European currencies, and the Chinese renminbi with its foreign businesses. In accordance with U.S. GAAP, these contracts are considered “derivatives not designated as hedging instruments.” Gains or losses on these instruments are reported in current earnings. The foreign currency forward contracts are recorded at fair value in the consolidated balance sheet at December 31, 2023 and 2022, as disclosed in Note 7 to the consolidated financial statements. The Company recognized in other charges (income), net a net loss of $19.7 million and a net loss of $21.6 million and a net gain of $13.5 million during the years ended December 31, 2023, 2022, and 2021, respectively, which offset the related net transaction gains (losses) associated with these contracts. At December 31, 2023 and 2022, these contracts had a notional value of $793.9 million and $930.3 million, respectively. The Company may be exposed to credit losses in the event of nonperformance by the counterparties to its derivative financial instrument contracts. Counterparties are established banks and financial institutions with high credit ratings. The Company believes that such counterparties will be able to fully satisfy their obligations under these contracts.

X
- Definition Financial Instruments [Abstract] + References No definition available. + Details
Name: | mtd_FinancialInstrumentsAbstract
Namespace Prefix: | mtd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//815/tableOfContent + Details
Name: | us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration